Vanguard Group
RPTX

Vanguard Group’s Repare Therapeutics RPTX Stock Holding History

Vanguard Group’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-52,857
Closed -$52.1K – 4321
2025
Q1 		$52.1K Sell
52,857
-1,408
-3% -$1.7K ﹤0.01% 4190
2024
Q4 		$71.1K Sell
54,265
-832
-2% -$2.48K ﹤0.01% 4188
2024
Q3 		$190K Sell
55,097
-448
-0.8% -$1.48K ﹤0.01% 4149
2024
Q2 		$183K Sell
55,545
-296
-0.5% -$1.06K ﹤0.01% 4177
2024
Q1 		$263K Sell
55,841
-6,818
-11% -$43.7K ﹤0.01% 4133
2023
Q4 		$457K Sell
62,659
-12,403
-17% -$69.4K ﹤0.01% 4064
2023
Q3 		$907K Buy
75,062
+500
+0.7% +$5.16K ﹤0.01% 3873
2023
Q2 		$789K Sell
74,562
-540
-0.7% -$5.56K ﹤0.01% 3971
2023
Q1 		$739K Hold
75,102
– – ﹤0.01% 3998
2022
Q4 		$1.1M Buy
75,102
+1,260
+2% +$18.8K ﹤0.01% 3879
2022
Q3 		$895K Buy
73,842
+600
+0.8% +$7.72K ﹤0.01% 4039
2022
Q2 		$1.02M Buy
73,242
+8,773
+14% +$103K ﹤0.01% 4077
2022
Q1 		$918K Buy
64,469
+360
+0.6% +$5.34K ﹤0.01% 4235
2021
Q4 		$1.35M Buy
64,109
+29,065
+83% +$685K ﹤0.01% 4172
2021
Q3 		$920K Buy
35,044
+1,270
+4% +$41K ﹤0.01% 4263
2021
Q2 		$1.05M Sell
33,774
-134
-0.4% -$4.39K ﹤0.01% 4140
2021
Q1 		$1.04M Buy
33,908
+2,489
+8% +$84.5K ﹤0.01% 4001
2020
Q4 		$1.08M Buy
+31,419
New +$939K ﹤0.01% 3809

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group's RPTX Position: Q2 2025 in Review

Vanguard Group sold out of Repare Therapeutics (RPTX) in Q2 2025, closing a stake of 52,857 shares — an estimated $52.1K sold.

Vanguard Group first reported a position in RPTX in Q4 2020 and held it in 18 quarters. The position peaked at $1.35M in Q4 2021. 50 funds tracked by Wall St. Rank hold RPTX as of Q2 2025.

  • Vanguard Group reported no remaining Repare Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Vanguard Group sold 52,857 Repare Therapeutics shares in Q2 2025, an estimated $52.1K.
  • Vanguard Group first reported a position in Repare Therapeutics in Q4 2020 and held it in 18 quarters.
  • Vanguard Group's Repare Therapeutics position peaked at $1.35M in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2025.

Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.